Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Phospho-Lck (Tyr505) (A3) rabbit mAb PE conjugate
Customers Also Viewed
|Description||Lck is a member of the Src family of non-receptor tyrosine kinases and plays a major role in T cell activation. Lck activates many downstream signaling pathways including Akt/mTOR, SAPK/JNK, PLCγ1, and RAS/MAPK. Phosphorylation of Lck at Tyr394 in the catalytic domain at the ATP-binding site stabilizes the open and active form, while phosphorylation at Tyr505 in the C-terminal domain promotes the closed, inactive conformation. Multiple small-molecule drugs used to treat leukemia have been shown to target inhibition of Lck, including imatinib and dasatinib. Lck is thus a promising target for suppressing T-cell responses for the treatment of inflammatory diseases or after organ transplantation.|
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Tyr505 of human phospho Lck|
|Formulation||1X PBS, 0.09% NaN3, 0.2% BSA|
|Recommended Usage||For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.|
|Pseudonyms||Tyrosine-protein kinase Lck, Leukocyte C-terminal Src kinase, LSK, Protein YT16, T cell-specific protein-tyrosine kinase|
|References||Serafin V, Capuzzo G, Milani G, et al. (2017) Blood. 130: 2750-2761.
Lee KC, Ouwehand I, Giannini AL, et al. (2010) Leukemia. 24: 896-900.
Flow cytometric analysis of Daudi Human Burkitt′s lymphoma cells untreated and unstained as negative control (blue) or untreated and stained (red) or treated with IFNa plus IL4 and stained (green) using Phospho-LCK (Y505) antibody LCKY505-A3 PE conjugate. Cat. #2302